Farag Kameel D.'s Form 4 filing
Akari Therapeutics Plc (AKTX) · filed Dec 18, 2025
- Accession no.
- 0001493152-25-028419
- Filed
- Dec 18, 2025, 9:57 PM ET
- Trade date
- Dec 16, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 derivative transactions. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Farag Kameel D.CIK 0002093620 | Officer (Interim CFO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 16, 2025 | American Depositary Shares representing Ordinary Shares | PPurchaseAcquired | +24,745 | –F4 | – | 24,745 | Direct | |
| Dec 16, 2025 | American Depositary Shares representing Ordinary Shares | PPurchaseAcquired | +24,745 | $0.4041F4 | +$9,999.45 | 24,745 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F4
The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041.
Referenced by the price of 2 transactions in Table II.